Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 30;6(3):e84.
doi: 10.15190/d.2018.4.

Gut Microbiome and the Response to Immunotherapy in Cancer

Andreea Lucia Stancu  1
Affiliations
Review

Gut Microbiome and the Response to Immunotherapy in Cancer

Andreea Lucia Stancu. Discoveries (Craiova). .

Abstract

Recent studies indicate that the composition of gut bacteria can influence the effectiveness of certain cancer immunotherapy drugs and that modulating the gut microbiome may expand the pool of patients benefiting from cancer immunotherapies. Checkpoint blockade therapy has been effective on several types of malignancies (e.g. melanoma, lung cancer, kidney cancer). However, the number of patients that do not respond, or only partially respond, to cancer immunotherapy is high. Recently, several human and mouse studies have shown that gut microbiome may be a significant determinant of the response to cancer immunotherapy. This review focuses on the recent advances in our understanding of the interaction between human gut microbiome and response to immunotherapy in cancer. The gut microbiome may serve as a theranostic biomarker, by acting both as a useful prognostic biomarker and a target in cancer therapy.

Keywords: Cancer; PD-1; PD-L1.; immunotherapy; microbiome; response to therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests: The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Figure 1. Exponential growth of the number of articles published between 2003-2018 related to the “cancer immunotherapy” and “microbioma”.
This graph is based on the PubMed publications data. Data for 2018 is collected for January-September 2018.
See this image and copyright information in PMC

References

    1. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. Robert Caroline, Thomas Luc, Bondarenko Igor, O'Day Steven, Weber Jeffrey, Garbe Claus, Lebbe Celeste, Baurain Jean-François, Testori Alessandro, Grob Jean-Jacques, Davidson Neville, Richards Jon, Maio Michele, Hauschild Axel, Miller Wilson H., Gascon Pere, Lotem Michal, Harmankaya Kaan, Ibrahim Ramy, Francis Stephen, Chen Tai-Tsang, Humphrey Rachel, Hoos Axel, Wolchok Jedd D. New England Journal of Medicine. 2011;364(26):2517-2526. - PubMed
    1. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Ribas Antoni, Hamid Omid, Daud Adil, Hodi F. Stephen, Wolchok Jedd D., Kefford Richard, Joshua Anthony M., Patnaik Amita, Hwu Wen-Jen, Weber Jeffrey S., Gangadhar Tara C., Hersey Peter, Dronca Roxana, Joseph Richard W., Zarour Hassane, Chmielowski Bartosz, Lawrence Donald P., Algazi Alain, Rizvi Naiyer A., Hoffner Brianna, Mateus Christine, Gergich Kevin, Lindia Jill A., Giannotti Maxine, Li Xiaoyun Nicole, Ebbinghaus Scot, Kang S. Peter, Robert Caroline. JAMA. 2016;315(15):1600. - PubMed
    1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. Borghaei Hossein, Paz-Ares Luis, Horn Leora, Spigel David R., Steins Martin, Ready Neal E., Chow Laura Q., Vokes Everett E., Felip Enriqueta, Holgado Esther, Barlesi Fabrice, Kohlhäufl Martin, Arrieta Oscar, Burgio Marco Angelo, Fayette Jérôme, Lena Hervé, Poddubskaya Elena, Gerber David E., Gettinger Scott N., Rudin Charles M., Rizvi Naiyer, Crinò Lucio, Blumenschein George R., Antonia Scott J., Dorange Cécile, Harbison Christopher T., Graf Finckenstein Friedrich, Brahmer Julie R. New England Journal of Medicine. 2015;373(17):1627-1639. - PMC - PubMed
    1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. Topalian Suzanne L., Hodi F. Stephen, Brahmer Julie R., Gettinger Scott N., Smith David C., McDermott David F., Powderly John D., Carvajal Richard D., Sosman Jeffrey A., Atkins Michael B., Leming Philip D., Spigel David R., Antonia Scott J., Horn Leora, Drake Charles G., Pardoll Drew M., Chen Lieping, Sharfman William H., Anders Robert A., Taube Janis M., McMiller Tracee L., Xu Haiying, Korman Alan J., Jure-Kunkel Maria, Agrawal Shruti, McDonald Daniel, Kollia Georgia D., Gupta Ashok, Wigginton Jon M., Sznol Mario. New England Journal of Medicine. 2012;366(26):2443-2454. - PMC - PubMed
    1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Sharma Padmanee, Hu-Lieskovan Siwen, Wargo Jennifer A., Ribas Antoni. Cell. 2017;168(4):707-723. - PMC - PubMed

LinkOut - more resources